BK KINYOUN KIT Distribuidor: http://www.cromakit.es
BK KINYOUN KIT. Para diagnóstico “in vitro”. UTILIDAD DIAGNÓSTICA. Los colorantes para tinción de Kinyoun se utilizan para realizar tinciones de cultivos o.
Revisions
For staining mycobacteria by the Kinyoun (cold). 1 x 250 mL. TB Decolorizer acid-fast procedure. 1 x 250 mL. TB Brilliant Green K. 1 x 250 mL. TB Stain Kit
Handbook on TB laboratory diagnostic methods in the European
Neelsen Kinyoun) and fluorochrome staining (auramine
Handbook on TB laboratory diagnostic methods in the European
Neelsen Kinyoun) and fluorochrome staining (auramine
Procedimientos en Microbiología Clínica
7 Jan 2014 Neelsen o variantes como la de Kinyoun donde los ... RealArt M. tuberculosis TM PCR kit. Consiste ... PNT-BK-01. TINCIÓN DE ZIEHL-NEELSEN.
Prevention Diagnosis and Management of Tuberculosis
6 Tuberculosis laboratory diagnosis This set of clinical practice guidelines was ... more sensitive compared to traditional Ziehl-Neelson or Kinyoun.
normax-general-catalogue-2019-150119.pdf
Our goals are set and clear: ? To provide our partners with a win-win Filtration set. 35 . Kitasato flask. 35 . Kitasato bottle ... TB Kinyoun Kit.
Colorantes
TINCIÓN KINYOUN. Producto. Referencia. Formato. Código de barras. Almacenaje. Estado. BK KINYOUN KIT. 992505. 3 x 250 ml. 18430155004698
Cromakit S.L.
Bk kinyoun kit 3x250 ml. 992505. Kit utilizado para realizar tinciones de cultivos o muestras que se sospecha que contienen micobacterias para el
BD Diagnostics Diagnostic Systems
Individual component of the TB Stain Kit K (Cat . No . 212522) for staining mycobacteria by the Kinyoun (cold) acid-fast procedure . BD Kinyoun (cold)
TECHNICAL DOCUMENT
Handbook on TB laboratory
diagnostic methods in the European UnionECDC TECHNICAL DOCUMENT
Handbook on TB laboratory diagnostic
methods for the European Union ii with support from Marieke J. van der Werf, Francis Drobniewski and Vladyslav Nikolayevskyy.This report was sent for consultation to the members of the ERLTB-Net network (see Appendix 1 for list of
contributors).The first version of this ECDC technical report, previously published as µMastering the basics of TB control:
handbook which was included as an annex. This report has now been revised, updated and renamed as the
Suggested citation: European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic
methods for the European Union, Stockholm: ECDC; 2016.Stockholm, March 2016
ISBN 978-92-9193-739-4
doi 10.2900/216384Catalogue number TQ-01-16-109-EN-N
© European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged Handbook on TB laboratory diagnostic methods for the EU TECHNICAL DOCUMENT iiiContents
Abbreviations ................................................................................................................................................ v
Background and introduction .......................................................................................................................... 1
1 Biosafety in the laboratory diagnosis of tuberculosis ....................................................................................... 4
1.1 Background and principles ................................................................................................................... 4
1.2 The containment laboratory (biosafety level 3) ...................................................................................... 5
1.3 The laboratory facility .......................................................................................................................... 6
1.4 Procedures ......................................................................................................................................... 7
1.5 Personal protective equipment (PPE)..................................................................................................... 7
1.6 The human resource component .......................................................................................................... 8
1.7 Specific laboratory tasks related to hazards ........................................................................................... 8
2 Quality assurance ...................................................................................................................................... 12
2.1 Background and principles ................................................................................................................. 12
2.2 Selection and implementation of tests ................................................................................................. 13
2.3 Validation ......................................................................................................................................... 13
2.4 Control and trend monitoring by key indicators .................................................................................... 14
2.5 Physical and environmental conditions ................................................................................................ 14
2.6 Equipment ........................................................................................................................................ 14
2.7 Management and staff ....................................................................................................................... 14
2.8 Documentation and registration .......................................................................................................... 15
2.9 Sampling guidance, review of requests and service to customers ........................................................... 15
2.10 Subcontracting, services and supplies ................................................................................................ 15
2.11 Complaints, errors and corrective actions ........................................................................................... 15
2.12 Improvements................................................................................................................................. 15
2.13 Reporting and releasing results ......................................................................................................... 16
3. Diagnosis of latent TB infection ................................................................................................................. 17
3.1 Background and principles ................................................................................................................. 17
3.2 The tuberculin skin test (TST) ............................................................................................................ 18
3.3 Interferon-DŽ UHOHMVH MVVM\V H*5$V .................................................................................................... 18
4. Smear microscopy .................................................................................................................................... 32
4.1 Background and principles ................................................................................................................. 32
4.2 Procedure 1: Ziehl-Neelsen (ZN) ......................................................................................................... 32
4.3 Procedure 2: Fluorochrome staining .................................................................................................... 34
4.4 Sample collection .............................................................................................................................. 35
4.5 Smear preparation ............................................................................................................................ 36
4.6 Staining procedures ........................................................................................................................... 36
4.7 Microscopy ....................................................................................................................................... 37
4.8 Recording and reporting .................................................................................................................... 38
4.9 Quality control .................................................................................................................................. 40
5. Culture tests for Mycobacterium tuberculosis complex ................................................................................. 42
5.1 Background and principles ................................................................................................................. 42
5.2 Biohazards and biosafety in the TB laboratory ...................................................................................... 42
5.3 Specimen collection, storage and transport .......................................................................................... 44
5.4 Homogenisation and decontamination of specimens ............................................................................. 45
5.5 Culture media: principles ................................................................................................................... 49
5.6 Solid media ....................................................................................................................................... 49
5.7 Culture tube inoculation ..................................................................................................................... 50
5.8 Culture incubation ............................................................................................................................. 51
5.9 Culture examination .......................................................................................................................... 51
6. Identification of M. tuberculosis and drug resistance in cultures/sputum using molecular assays and immunoassays .. 54
6.1 Background and principles ................................................................................................................. 54
6.2 Procedure 1: Chromatographic immunoassay for the qualitative detection of Mycobacterium tuberculosis complex
from cultures ........................................................................................................................................... 54
6.3 Procedure 2: Line probe assay for identification of the genus Mycobacterium and 16 different mycobacterial
species including M. tuberculosis complex from culture .............................................................................. 55
6.4 Procedure 3: Line probe assay for identification of M. tuberculosis complex and detection of rifampicin resistance in M.
tuberculosis ............................................................................................................................................. 57
6.5 Procedure 4: Line probe assay for identifying species from genus Mycobacterium and detecting potential
MDR- and XDR-TB from cultures and smear-positive specimens .................................................................. 62
6.6 Procedure 5: Nucleic acid hybridisation test for the identification of M. tuberculosis complex .................... 69
6.7 Procedure 6: Single-use sample-processing cartridge system with integrated multicolour real-time PCR capacity for
detection & identification of M. tuberculosis complex bacteria and detection of rifampicin resistance ............................. 70
7. First- and second-line drug susceptibility testing for Mycobacterium tuberculosis complex ............................... 72
TECHNICAL REPORT Handbook on TB laboratory diagnostic methods for the EU iv7.1 Background and principles ................................................................................................................. 72
7.2 Procedure 1: General method ± DST by culture .................................................................................... 72
7.4 Procedure 3: Resistance ratio method ................................................................................................. 76
7.5 Procedure 4: Drug susceptibility testing in liquid media (MGIT 960) ....................................................... 78
7.6 Procedure 5: Other methods for first-line drug susceptibility testing ....................................................... 79
8. Molecular typing of Mycobacterium tuberculosis complex isolates ................................................................. 83
8.1 Background and principles ................................................................................................................. 83
8.2 Procedure 1: Spoligotyping ................................................................................................................ 83
8.3 Procedure 2: MIRU-VNTR typing ......................................................................................................... 85
8.4 Procedure 3: RFLP typing ................................................................................................................... 86
8.5 General considerations on routine genotyping methods ........................................................................ 86
8.6 Procedure 4: whole genome sequencing ............................................................................................. 86
8.7 Materials .......................................................................................................................................... 87
8.8 Results/interpretation ........................................................................................................................ 88
8.9 Quality control .................................................................................................................................. 88
8.10 Biosafety ........................................................................................................................................ 88
9. Use and validation of disinfectants for Mycobacterium tuberculosis ............................................................... 92
9.1 Liquid disinfection ............................................................................................................................. 92
9.2 Gaseous disinfection .......................................................................................................................... 94
10. Information for physicians: laboratory diagnosis of tuberculosis ± first steps ................................................ 98
10.1 Introduction .................................................................................................................................... 98
10.2 General considerations regarding the diagnosis of tuberculosis ............................................................ 98
10.3 Specific considerations regarding diagnosis of tuberculosis .................................................................. 99
10.4 Information flow from microbiologist to physician and instructions regarding tuberculosis diagnosis ...... 100
Figures
Figure 1.1 Biohazard warning sign for laboratory doors ..................................................................................... 5
Figure 3.1 Potential outcomes of human host infection by M. tuberculosis ........................................................ 18
Figure 4.1 Microscope components ................................................................................................................ 37
Figure 4.2 AFB smear microscopy of biological specimens ................................................................................ 39
Figure 4.3 AFB smear microscopy of M. tuberculosis cultures .......................................................................... 39
Figure 5.1 Minimal examination schedule for solid cultures ............................................................................. 52
Figure 6.1 Examples of chromatographic immunoassays for qualitative detection of M. tuberculosis complex ..................... 55
Figure 6.2 Interpretation scheme for INNO-LiPA ............................................................................................. 57
Figure 6.3 Interpretation of LiPA ................................................................................................................... 61
Figure 6.4 Interpretation sheet for GenoType Mycobacterium CM ..................................................................... 65
Figure 6.5 Interpretation sheet for GenoType Mycobacterium AS ..................................................................... 66
Figure 6.6 Interpretation sheet for GenoType Mycobacterium MTBC ................................................................. 66
Figure 6.7 Interpretation sheet for GenoType Mycobacterium MTBDRPlus ......................................................... 67
Figure 6.8 Interpretation sheet for GenoType Mycobacterium MTBDRs ............................................................. 67
Tables
Table 1.1 Examples of personal protective equipment ...................................................................................... 8
Table 2.1 Overall scope of ISO 17025 and ISO 15189 .................................................................................... 12
Table 2.2 Central terms and abbreviations in quality assurance ....................................................................... 13
Table 3.1 List of national LTBI diagnosis guidelines ........................................................................................ 19
Table 3.2 QuantiFERON-TB Gold results interpretation .................................................................................... 24
Table 3.3 QuantiFERON-TB Gold PLUS results interpretation ........................................................................... 24
Table 3.4 Materials provided by the manufacturer .......................................................................................... 26
Table 4.1 Equipment required for smear preparation and staining .................................................................... 36
Table 4.2 Reporting of microscopy smears .................................................................................................... 38
Table 4.3 Common causes of error in smear microscopy ................................................................................. 40
Table 7.1 Solvents and diluents ..................................................................................................................... 74
Table 7.2 Calculation of modal MIC value ....................................................................................................... 76
Table 7.3 Examples of MIC interpretation ....................................................................................................... 77
Table 7.4 Critical concentrations of the most important first-line and second-/third-line drugs ............................ 78
Table 9.1 Differences between the two major gaseous hydrogen peroxide technologies, Steris VHP and Bioquell HPV .............. 95
Handbook on TB laboratory diagnostic methods for the EU TECHNICAL DOCUMENT vAbbreviations
AFB Acid-fast bacilli
BCG Bacillus Calmette-Guérin
BD Becton and Dickinson
BSC Biological safety cabinet
BSL Biosafety level
CFU Colony forming units
CSF Cerebral spinal fluid
CRI Colorimetric redox indicator
CXR Chest X-ray
DNA Deoxyribonucleic acid
DST Drug susceptibility testing
EEA European Economic Area
ENP European Neighbourhood Policy
EPTB Extrapulmonary tuberculosis
ERLN-TB European Reference Laboratory Network for Tuberculosis (2010±2014) ERLTB-Net European Reference Laboratory Network for Tuberculosis (from 2014)EQA External quality assessment
EU European Union
HEPA filter High-efficiency particulate air filterHPF High-power field
IATA International Air Transport Association
IFN-Ȗ Interferon-gamma
INSTAND e.V. Society for promoting quality assurance in medical laboratoriesIGRA Interferon-gamma release assay
IQA Internal quality assessment
ISO International Organization for StandardizationLED Light-emitting diode
LTBI Latent TB infection
MGIT Mycobacteria growth indicator tube
MIC Minimum inhibitory concentration
MIRU Mycobacterial interspersed repetitive units
MODS Microscopically observed drug susceptibility
MTBC Mycobacterium tuberculosis complex
NAAT Nucleic-acid amplification test
NRA Nitrate reductase assay
NRL National reference laboratory
NTM Non-tuberculous mycobacteria
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PPD Purified protein derivative
PPE Personal protective equipment
PPV Positive predictive value
QA Quality assurance
QC Quality control
RFLP Restriction fragment length polymorphism
RNI Reactive nitrogen intermediates
SDS Sodium dodecyl sulfate
SNP Single nucleotide polymorphism
SOP Standard operating procedures
TB Tuberculosis
TST Tuberculin skin test
UKAS United Kingdom Accreditation Service
UK NEQAS UKAS accredited proficiency testing provider No. 4715VNTR Variable number tandem repeat
ZN Ziehl-Neelsen (staining method)
TECHNICAL DOCUMENT Handbook on TB laboratory diagnostic methods for the EU 1Background and introduction
Francis Drobniewski
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is
the basis for both individual patient treatment and surveillance.In 2007, a survey of existing mycobacterial laboratory services and quality control practices throughout the EU
confirmed the key role of national reference laboratories (NRL) for TB and their services. The main conclusion of
the survey was that a network of reference laboratories for tuberculosis could contribute to improving the
performance of mycobacterial laboratories in Europe.Based on these results, the European Reference Laboratory Network for Tuberculosis (ERLN-TB) was launched in
January 2010, with the aim of strengthening TB diagnostics in the European Union. ERLN-TB was funded and
coordinated by ECDC. One or two officially nominated reference laboratories from each Member State joined the
network, along with those in EEA countries and EU candidate countries.Following the success of the ERLN-TB network, in 2014 ECDC commissioned a renewal of the network (now called
quotesdbs_dbs25.pdfusesText_31[PDF] BK-390 BK-380 pour MKL BK-390 BK-380 für MKL
[PDF] BKB News - Berufskolleg Bottrop
[PDF] BKC JUDO - Bushido Kai Canada
[PDF] BKit de montage sur paroi du Terminator ECM-R
[PDF] BKK Bergisch Land
[PDF] BKK Fahr
[PDF] BKK FTE Beitrittserklärung
[PDF] BKK GILDEMEISTER SEIDENSTICKER, Postfach 14 01 60, 33621
[PDF] BKK MOBIL OIL: Die Familie wächst.
[PDF] BKK Salzgitter SEPA-Basislastschriftmandat
[PDF] BKK vor Ort
[PDF] BKMF e.V.
[PDF] BKN230-24MP
[PDF] BKS helius - Sperrschließung